ETBX 011

Drug Profile

ETBX 011

Alternative Names: Ad5 [E1-, E2B-]-CEA(6D); AD5 CEA vaccine; Ad5[E1-,E2b-]-CEA vaccine; CEA-targeted vaccine - Etubics; ETBX-011

Latest Information Update: 29 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Etubics Corporation
  • Developer Etubics Corporation; NantCell
  • Class Cancer vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Colorectal cancer; Pancreatic cancer; Solid tumours

Most Recent Events

  • 01 Aug 2017 Phase-I/II clinical trials in Pancreatic cancer (Combination therapy, Second-line therapy or greater) in USA (unspecified route) (NCT03136406)
  • 26 Jun 2017 Phase-I/II clinical trials in Colorectal cancer (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (SC)
  • 20 Jun 2017 NantCell plans the phase Ib/II QUILT-3.048 trial for Urogenital cancer (Second-line therapy or greater, Combination therapy) (NCT03197571)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top